Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BMS-986527 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on BMS-986527, a putative CD70-targeting chimeric antigen receptor T-cell (CAR-T) therapy (Oct 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BMS-986527 | BMS 986527|BMS986527 | CD70 Immune Cell Therapy 12 | Limited information is currently available on BMS-986527, a putative CD70-targeting chimeric antigen receptor T-cell (CAR-T) therapy (Oct 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07848295 | Phase I | BMS-986527 + Nivolumab BMS-986527 + Cabozantinib BMS-986527 | A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) | Not yet recruiting | USA | NLD | ITA | FRA | ESP | DEU | BEL | 0 |